375 related articles for article (PubMed ID: 17433324)
1. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease.
Lechel A; Holstege H; Begus Y; Schienke A; Kamino K; Lehmann U; Kubicka S; Schirmacher P; Jonkers J; Rudolph KL
Gastroenterology; 2007 Apr; 132(4):1465-75. PubMed ID: 17433324
[TBL] [Abstract][Full Text] [Related]
2. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression.
Farazi PA; Glickman J; Horner J; Depinho RA
Cancer Res; 2006 May; 66(9):4766-73. PubMed ID: 16651430
[TBL] [Abstract][Full Text] [Related]
3. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma.
Farazi PA; Glickman J; Jiang S; Yu A; Rudolph KL; DePinho RA
Cancer Res; 2003 Aug; 63(16):5021-7. PubMed ID: 12941829
[TBL] [Abstract][Full Text] [Related]
4. Telomeres and telomerase: a dual role in hepatocarcinogenesis.
Satyanarayana A; Manns MP; Rudolph KL
Hepatology; 2004 Aug; 40(2):276-83. PubMed ID: 15368430
[TBL] [Abstract][Full Text] [Related]
5. Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene.
Jaskelioff M; Song W; Xia J; Liu C; Kramer J; Koido S; Gendler SJ; Calderwood SK; Gong J
Oncogene; 2009 Dec; 28(48):4225-36. PubMed ID: 19734944
[TBL] [Abstract][Full Text] [Related]
6. Contrasting effects of telomere shortening on organ homeostasis, tumor suppression, and survival during chronic liver damage.
Wiemann SU; Satyanarayana A; Buer J; Kamino K; Manns MP; Rudolph KL
Oncogene; 2005 Feb; 24(9):1501-9. PubMed ID: 15608677
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status.
Saini N; Srinivasan R; Chawla Y; Sharma S; Chakraborti A; Rajwanshi A
Liver Int; 2009 Sep; 29(8):1162-70. PubMed ID: 19627485
[TBL] [Abstract][Full Text] [Related]
8. Regulation of telomerase and its hTERT messenger in colorectal cancer.
Boldrini L; Faviana P; Gisfredi S; Donati V; Zucconi Y; Ursino S; Simi P; Baldinotti F; Berti P; Galleri D; Materazzi G; Basolo F; Miccoli P; Pingitore R; Fontanini G
Oncol Rep; 2004 Feb; 11(2):395-400. PubMed ID: 14719074
[TBL] [Abstract][Full Text] [Related]
9. Telomere length variation and maintenance in hepatocarcinogenesis.
Yokota T; Suda T; Igarashi M; Kuroiwa T; Waguri N; Kawai H; Mita Y; Aoyagi Y
Cancer; 2003 Jul; 98(1):110-8. PubMed ID: 12833463
[TBL] [Abstract][Full Text] [Related]
10. Telomerase reverse transcriptase gene amplification in hepatocellular carcinoma.
Takuma Y; Nouso K; Kobayashi Y; Nakamura S; Tanaka H; Matsumoto E; Fujikawa T; Suzuki M; Hanafusa T; Shiratori Y
J Gastroenterol Hepatol; 2004 Nov; 19(11):1300-4. PubMed ID: 15482538
[TBL] [Abstract][Full Text] [Related]
11. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions.
Lantuejoul S; Soria JC; Morat L; Lorimier P; Moro-Sibilot D; Sabatier L; Brambilla C; Brambilla E
Clin Cancer Res; 2005 Mar; 11(5):2074-82. PubMed ID: 15756034
[TBL] [Abstract][Full Text] [Related]
12. Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma.
Plentz RR; Schlegelberger B; Flemming P; Gebel M; Kreipe H; Manns MP; Rudolph KL; Wilkens L
Hepatology; 2005 Sep; 42(3):522-6. PubMed ID: 16116624
[TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis.
Oh BK; Kim YJ; Park YN; Choi J; Kim KS; Park C
Am J Gastroenterol; 2006 Apr; 101(4):831-8. PubMed ID: 16494581
[TBL] [Abstract][Full Text] [Related]
14. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
Zhang Y; Ma H; Zhang J; Liu S; Liu Y; Zheng D
Life Sci; 2008 Jun; 82(23-24):1154-61. PubMed ID: 18485417
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of PinX1 in human hepatocellular carcinoma.
Oh BK; Chae KJ; Park C; Park YN
Oncol Rep; 2004 Oct; 12(4):861-6. PubMed ID: 15375513
[TBL] [Abstract][Full Text] [Related]
16. Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus.
Habib NA; Mitry RR; Sarraf CE; Jiao LR; Havlík R; Nicholls J; Jensen SL
Cancer Gene Ther; 2002 May; 9(5):414-20. PubMed ID: 11961664
[TBL] [Abstract][Full Text] [Related]
17. Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse.
Khoo CM; Carrasco DR; Bosenberg MW; Paik JH; Depinho RA
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):3931-6. PubMed ID: 17360455
[TBL] [Abstract][Full Text] [Related]
18. [Expression of human telomerase reverse transcriptase gene in HCC does not depend on proliferating cell nuclear antigen and P53].
Zhang D; Li KZ; Dou KF; Gao ZQ; Song ZS; Zhao QC; Fu YC
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):721-2. PubMed ID: 15555445
[TBL] [Abstract][Full Text] [Related]
19. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.
Djojosubroto MW; Chin AC; Go N; Schaetzlein S; Manns MP; Gryaznov S; Harley CB; Rudolph KL
Hepatology; 2005 Nov; 42(5):1127-36. PubMed ID: 16114043
[TBL] [Abstract][Full Text] [Related]
20. Telomeres and telomerase in aging, regeneration and cancer.
Djojosubroto MW; Choi YS; Lee HW; Rudolph KL
Mol Cells; 2003 Apr; 15(2):164-75. PubMed ID: 12803478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
